

Title: High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.

Authors: Adams et al.

Publication: Cytometry Part A, March 2019

Table Title: CyTOF antibody panel markers

Data source: Supplementary Table S1: CyTOF antibody panel markers

Antigen	Clone	Metal Isotope	Purpose
CD45*	HI30	141Pr	Leukocytes
CD20*	2H7	142Nd	B lymphocytes
CD3*	UCHT1	143Nd	T lymphocytes
CD11b*	ICRF44	144Nd	Monocytes, NK
CD4*	RPA-T4	145Nd	T helper lymphocytes
CD8*	RPA-T8	146Nd	Cytotoxic T lymphocytes
CD66b*	80H3	147Sm	Granulocytes
CD34*	581	148Nd	Hematopoietic progenitor cells
CD45RO*	UCHL1	149Sm	Memory T lymphocytes
CD138* <sup>BM</sup>	MI15	150Nd	Plasma cells, multiple myeloma cells
CD33*	WM53	151Eu	Myeloid cells
CD55	MEM118	152Sm	Complement inhibition
CD16*	3G8	153Eu	Proinflammatory monocytes, NK subset, granulocytes
CD45RA*	HI100	154Sm	Naive T lymphocytes
CD27*	3155001B	155Gd	Memory B lymphocytes, T lymphocytes
CD152 (CTLA4)	L3D10	156Gd	Regulatory T cells, T cell activation
CD137	4B4-1	158Gd	Activated NK cells
CD123*	3G8	159Tb	Plasmacytoid dendritic cells, basophils
CD69	FN50	160Dy	T cell early activation
CD28*	CD28.2	161Dy	T cell co-stimulation
CD11c*	Bu15	162Dy	Monocytes, myeloid dendritic cells
Granzyme B	GB11	163Dy	Activated T cells, NK cells
CD15*	W6D3	164Dy	Granulocytes
CD127*	eBioRDR5	165Ho	Activated and regulatory T lymphocytes
CD134 (OX40)	ACT35	166Er	T cell activation
CD19*	HIB19	167Er	B lymphocytes
CD269 (BCMA)	Vicky	168Er	Plasma cells
CD25*	M-A251	169Tm	Activated and regulatory T lymphocytes
CD279(PD1)	EH12-1	170Er	T cell co-inhibitory receptor/exhaustion
CD14*	HCD14	171Yb	Monocytes, macrophages
CD38	Hymab	172Yb	Daratumumab target, activation, plasma cells
Vista	GG8	173Yb	T cell co-inhibitory receptor
HLA-DR*	646-6	174Yb	Dendritic cells, monocytes, B lymphocytes, T cell activation
CD59	MEM43	175Lu	Complement inhibition
CD56*	R19-760	176Yb	NK and NKT cells
DNA	intercalator	191Ir, 193 Ir	Nucleated cells

Abbreviations: BM, bone marrow; NK, natural killer cell.

\*Assigned as stable markers for SPADE analysis.

\*<sup>BM</sup> Only used as stable marker for BM samples.

Fc blocking reagent used: TruStain FcX (BioLegend)

Staining Protocol detailed in Supplementary Methods section "Sample Sources and Staining"